Login to Your Account

Other News To Note

Friday, October 5, 2012

• Sigma-Tau Pharmaceuticals Inc., of Gaithersburg, Md., said the FDA approved Cystaran (cysteamine ophthalmic solution) 0.44 percent, a topical ophthalmic therapeutic developed in partnership with the National Institutes of Health, for the treatment of corneal cysteine crystal accumulation as a result of cystinosis. Cystaran is designated an orphan drug in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription